[Anti-VEGF therapy resistance in neovascular age-related macular degeneration]
- PMID: 28980574
- DOI: 10.17116/oftalma20171334103-108
[Anti-VEGF therapy resistance in neovascular age-related macular degeneration]
Abstract
With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections.
В связи с увеличением численности пожилого населения в большинстве развитых стран ВОЗ определяет возрастную макулярную дегенерацию (ВМД) как одну из основных причин слепоты в мире. Основной процент инвалидности приходится на долю экссудативной, или неоваскулярной, формы ВМД. На сегодняшний день в мире суммарно доступны 5 анти-VEGF-препаратов, рекомендованных для лечения экссудативной формы ВМД: пегаптанид, ранибизумаб, бевацизумаб, афлиберцепт и конберцепт. Несмотря на значительный прогресс в лечении неоваскулярной формы ВМД, связанный с внедрением в клиническую практику анти-VEGF-препаратов, у ряда пациентов отмечают недостаточный ответ или его отсутствие при стандартных режимах их введения, а иногда и снижение терапевтического эффекта после повторных интравитреальных инъекций.
Keywords: aflibercept; age-related macular degeneration; anti-VEGF therapy; bivacizumab; chroidal neovascularization; ranibizumab; resistance; retina.
Similar articles
-
Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.Expert Rev Clin Pharmacol. 2015;8(5):541-8. doi: 10.1586/17512433.2015.1075879. Epub 2015 Aug 10. Expert Rev Clin Pharmacol. 2015. PMID: 26289225
-
Profile of conbercept in the treatment of neovascular age-related macular degeneration.Drug Des Devel Ther. 2015 Apr 22;9:2311-20. doi: 10.2147/DDDT.S67536. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25960634 Free PMC article. Review.
-
An update on the pharmacotherapy of neovascular age-related macular degeneration.Expert Opin Pharmacother. 2013 Jun;14(8):1017-28. doi: 10.1517/14656566.2013.787410. Epub 2013 Apr 8. Expert Opin Pharmacother. 2013. PMID: 23560774 Review.
-
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7. Angiogenesis. 2015. PMID: 26346237 Review.
-
Anti-VEGF agents for age-related macular degeneration.Expert Opin Ther Pat. 2010 Jan;20(1):103-18. doi: 10.1517/13543770902762885. Expert Opin Ther Pat. 2010. PMID: 20021287 Review.
Cited by
-
Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial.Trials. 2021 Jan 19;22(1):69. doi: 10.1186/s13063-021-05025-x. Trials. 2021. PMID: 33468208 Free PMC article.
-
Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study).Medicine (Baltimore). 2019 May;98(20):e15735. doi: 10.1097/MD.0000000000015735. Medicine (Baltimore). 2019. PMID: 31096535 Free PMC article.
-
The natural preferred retinal locus in patients with macular disease.Sci Rep. 2025 Jul 14;15(1):25348. doi: 10.1038/s41598-025-88421-6. Sci Rep. 2025. PMID: 40659772 Free PMC article.
-
Enhancing the Inhibition of Corneal Neovascularization Efficacy by Self-Assembled into Supramolecular Hydrogel of Anti-Angiogenic Peptide.Int J Nanomedicine. 2024 Jul 25;19:7605-7616. doi: 10.2147/IJN.S465965. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39081898 Free PMC article.
-
Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography.Eye Vis (Lond). 2022 May 1;9(1):16. doi: 10.1186/s40662-022-00287-1. Eye Vis (Lond). 2022. PMID: 35505390 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical